Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma

Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma

(2018) Kentaro Tokumo et al.   LUNG CANCER

Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies

(2018) Jiang-Dong Sui et al.   Drug Design Development and Therapy

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab

(2018) Ayumu Takahashi et al.   INTERNAL MEDICINE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

(2017) Justin C. Kao et al.   JAMA Neurology

Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab

(2016) Samer Tabchi et al.   LUNG CANCER

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials

(2016) Seongseok Yun et al.   Cancer Medicine

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

(2015) Abhisek Swaika et al.   MOLECULAR IMMUNOLOGY

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

(2015) Shannon K. Quirk et al.   Translational Research

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY